Every 8-K that ODYSSEY HEALTH INC (ODYY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ODYY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ODYY filings page.
Odyssey Health, Inc. disclosed that it entered into Amendment No. 12 with LGH Investments, LLC to its existing convertible promissory note. The amendment, effective as of April 30, 2026, extends the note’s maturity date to September 30, 2026. All other terms and conditions of the note remain unchanged.
Odyssey Health, Inc. reports that NeuRX Health, Inc. sent a formal letter on May 6, 2026 stating that the definitive agreement between NeuRX and Odyssey dated October 14, 2025, which closed on April 21, 2026, is immediately cancelled.
The letter relates to NeuRX’s sublicensing of Davion Healthcare Plc’s BreastCheck product to Odyssey and refers to issues with required consents and approvals under Davion’s arrangements. Odyssey has filed the NeuRX revocation letter as an exhibit to this report.
Odyssey Health, Inc. closed a definitive sub-license agreement giving its subsidiary, Odyssey Medical Devices, exclusive worldwide marketing and distribution rights to BreastCheck™, a non-invasive at-home breast screening test. BreastCheck™ delivers results in about 15 minutes and is intended as a first-line adjunct to mammography and clinical exams.
The test is registered with regulators in the U.S., European Union, and United Kingdom, supporting an international commercial footprint. Odyssey highlights this agreement as a key step in shifting toward revenue-generating products, with commercial sales of BreastCheck™ anticipated in the second half of the year and a focus on recurring revenue from repeat screening use.
Odyssey Health, Inc. entered into several note amendments to push out upcoming debt maturities. On January 30, 2026, the company signed four Amendment No. 12 agreements with two directors and two officers to extend the maturity of their Convertible Promissory Notes to January 31, 2027.
On the same date, Odyssey amended a Convertible Promissory Note with LGH Investments, LLC (Amendment No. 11) to extend its maturity to April 30, 2026. It also amended a Promissory Note with accredited investor Jonathan Lutz (Amendment No. 5) to extend maturity to January 31, 2027, and a Promissory Note with accredited investor Peter J. D’Arruda (Amendment No. 2, entered February 2, 2026 and effective January 31, 2026) to the same January 31, 2027 date. Forms of these amendments are filed as exhibits.
Odyssey Health, Inc. entered a long-term Maintenance Agreement with Mast Hill Fund under which Odyssey will provide facility services through the first business day of February 2034. Mast Hill or its designee will pay service fees totaling approximately $245,000 per year.
In exchange for these fees, Odyssey issued Mast Hill a $2,262,000 convertible promissory note bearing 10% annual interest and maturing on November 13, 2026, convertible into common stock at 85% of the lowest volume weighted average price over the preceding 10 trading days. Odyssey will remit net service fees to Mast Hill as payments on this note.
Odyssey also signed a Securities Purchase Agreement allowing issuance of a convertible note of up to $25,000,000 in multiple tranches with a 10% original issue discount, implying maximum proceeds of $22,250,000 before costs, convertible on the same 85% VWAP formula. The first $500,000 tranche delivered net proceeds of $437,500 and included Warrants for 1,538,461 shares at $0.001 per share, with a requirement to have an effective registration statement within 60 days of each tranche.
Odyssey Health, Inc. entered into a Master Technology and Sub-license Agreement with NeuRX Health, Inc., securing exclusive, worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities. The definitive agreement, managed through subsidiary Odyssey Medical Devices, Inc., is subject to certain closing conditions.
The agreement includes customary representations, warranties, covenants, and mutual indemnification, and contemplates customary ancillary documents at closing. The company highlighted risks tied to development and commercialization timelines, funding needs, and intellectual property protection. On October 16, 2025, Odyssey issued a press release announcing the signing; it is filed as Exhibit 99.1, with the agreement as Exhibit 10.1.
Odyssey Health, Inc. reported that on October 9, 2025 it entered into Amendment No. 6 to its promissory note issued on December 13, 2022 with Mast Hill Fund, L.P.
Under this amendment, the maturity date of the promissory note is extended to April 30, 2026, giving the company more time before the debt comes due. The amendment also deletes Section 4.16 titled “Amortization Payments” in its entirety, while all other terms and conditions of the note remain the same.
Odyssey Health, Inc. entered into a new short-term financing arrangement with a private investor. On October 3, 2025, the company received $100,000 under a one-year promissory note effective as of October 1, 2025, bearing interest at 18% per year. This provides near-term cash to the business but at a relatively high interest cost.
As part of this financing, Odyssey issued the investor a warrant to purchase 100,000 shares of its common stock at an exercise price of $0.10 per share
Odyssey Health, Inc. entered into Amendment No. 10 with LGH Investments, LLC, effective as of July 31, 2025, to modify an existing convertible promissory note. Under this amendment, the maturity date of the note is extended to January 31, 2026, giving the company additional time before the debt becomes due, while all other terms and conditions of the note remain unchanged.
The company has filed the form of Amendment No. 10 to the convertible promissory note as an exhibit, making the detailed terms available for review. This update reflects a negotiated change with a financing partner rather than a new financing arrangement.